Latest

OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy

Leap Therapeutics Acquires Flame Biosciences

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

Graybug and CalciMedica Enter into Definitive Merger Agreement

Scientific Inquirer: Industry Matters: From Elite Responders to M2 macrophages – OncoResponse’s approach to cancer immunotherapy

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis®

Cellworks: Predictions of Overall Survival And Progression-Free Survival For Therapeutic Interventions In Glioblastoma Multiforme